Clinical trial
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium…
NCT00269399 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00269399 |
|---|---|
| Title | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) |
| Official title | A Double-Blind, Randomized, Controlled Trial of Rifaximin Compared to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Clostridium Infections, Diarrhea |
| Intervention type | Drug |
| Interventions | Rifaximin (Xifaxan), Vancomycin |
| Enrollment | 237 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Dec 23, 2005 |
| Last update posted | Oct 14, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: